Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year
Rhea-AI Summary
Intelligent Bio Solutions (Nasdaq: INBS) expects preliminary unaudited fiscal Q2 2026 revenue to rise about 48% YoY, and fiscal H1 2026 total revenue to be approximately $2.01 million (up 36% YoY).
Reader sales are expected to increase ~104% YoY in Q2 while cartridge sales are up ~33% Q2 / 38% H1, with accessories/training also growing. Results are preliminary and subject to quarter-end close and Form 10-Q filing during the week of Feb 9, 2026.
Positive
- Fiscal Q2 revenue growth of ~48% YoY
- Fiscal H1 total revenue of $2.01 million (up 36% YoY)
- Reader unit sales growth of ~104% YoY in Q2
- Cartridge sales growth of ~33% Q2 / 38% H1
Negative
- Reported results are preliminary and unaudited, subject to adjustments after quarter-end close
- Absolute revenue remains modest at $2.01 million for H1, limiting scale benefits near term
News Market Reaction – INBS
On the day this news was published, INBS declined 9.13%, reflecting a notable negative market reaction. Argus tracked a peak move of +39.2% during that session. Argus tracked a trough of -15.4% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $850K from the company's valuation, bringing the market cap to $8M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
INBS fell about 6.14% while key peers showed mixed moves: several names like ALUR and NVNO were down, SINT was slightly positive, and scanner activity highlighted one strong gainer (NXL) and one notable decliner (PAVM). This points to stock-specific dynamics rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 28 | Clinical study update | Positive | +2.9% | New clinical studies initiated to support FDA 510(k) submission. |
| Jan 02 | Private placement close | Negative | -17.2% | Closing of $10.0M private placement with new warrants issued. |
| Dec 31 | Private placement announce | Negative | +132.4% | Announcement of $10.0M private placement and warrant issuance. |
| Dec 31 | Manufacturing partnership | Positive | +132.4% | New manufacturing partner expected to cut costs and boost capacity. |
| Dec 18 | Strategic partnership | Positive | +18.4% | Alliance with Vlepis to expand non-invasive screening and monitoring. |
INBS has often reacted positively to partnerships and clinical progress, while capital raises have drawn mixed reactions, including one sharp rally and one notable selloff.
Over the past few months, INBS reported multiple strategic steps: new partnerships with Syrma Johari MedTech and Vlepis, a substantial private placement around $10.0 million, and the launch of additional clinical studies supporting an FDA 510(k) submission. These updates often coincided with strong positive moves, especially around manufacturing and strategic alliances. The current preliminary revenue growth announcement for fiscal Q2 and H1 2026 follows this sequence of commercial scaling, manufacturing expansion, and regulatory preparation aimed at broader market entry.
Regulatory & Risk Context
An effective S-3 resale registration covers 6,896,550 shares tied to a recent private placement. The company will not receive proceeds from resale, but could receive up to about $18.87 million if all related warrants are exercised for cash. The filing notes that the large registered block could pressure the stock price if sold quickly.
Market Pulse Summary
The stock moved -9.1% in the session following this news. A negative reaction despite strong preliminary revenue growth would fit a pattern where capital structure and overhang concerns weighed on sentiment. Recent filings registered 6,896,550 shares for resale, with comments that rapid selling could pressure the stock, and the company previously undertook a 1-for-10 reverse split. Even with fiscal H1 2026 revenue around $2.01 million and solid reader and cartridge growth, these structural factors could have amplified downside moves.
Key Terms
razor-razorblade business model financial
form 10-q regulatory
AI-generated analysis. Not financial advice.
Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories
Reader sales expected to post year-over-year growth of more than
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results for the fiscal second quarter and first half 2026 ended December 31, 2025.
The Company expects to report strong revenue growth across all product categories for the three- and six-month periods ended December 31, 2025.
Six-Month Period (Fiscal H1 ’26, July - December 2025):
- Total revenue expected to be approximately
$2.01 million , representing a36% increase year-over-year - Sales of cartridges expected to increase approximately
38% year-over-year - Sales of readers expected to increase approximately
50% year-over-year - Other sales (accessories, training) expected to increase approximately
10% year-over-year
Three-Month Period (Fiscal Q2 ’26, October - December 2025):
- Revenue expected to increase approximately
48% year-over-year - Sales of cartridges expected to increase approximately
33% year-over-year - Sales of readers expected to more than double, increasing approximately
104% year-over-year - Other sales (accessories, training) expected to increase approximately
36% year-over-year
“We are very pleased with our expected results, showing strong second-quarter performance and reader sales more than doubling year-over-year," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "This expansion of our installed base is the foundation of our razor-razorblade business model, as each reader placement creates a long-term relationship that drives recurring cartridge revenue. The anticipated
The preliminary unaudited revenue results for the fiscal second quarter and first half 2026, ended December 31, 2025, are based on information available to management as of the date of this press release and are, therefore, subject to adjustments based on the Company’s completion of its quarter-end financial close process. The Company expects to disclose financial results for the fiscal second quarter and first half 2026 ended December 31, 2025, in its upcoming Quarterly Report on Form 10-Q, expected to be filed with the Securities and Exchange Commission during the week commencing February 09, 2026.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit: https://ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
What revenue growth did Intelligent Bio Solutions (INBS) report for fiscal Q2 2026?
How much revenue did INBS expect for the first half of fiscal 2026 (H1)?
What drove the strong reader sales growth for INBS in fiscal Q2 2026?
How did INBS cartridge sales perform in fiscal Q2 and H1 2026?
Are INBS’s announced figures final and where will investors see audited results?
What does INBS’s reader and cartridge growth mean for shareholders of INBS?
